HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Split To Have Limited China Business Impact?

With Conglomerate Model Outdated, US Health Care Giant Pivots To Agility

Executive Summary

China is a major emerging market for J&J’s pharma, medical and consumer health businesses and the planned spinout of the consumer business is likely to allow the US giant to focus on key new drugs in a fast-changing and competitive market while retaining medtech growth. But the consumer sector will continue to face challenges and might learn from similar moves by other multinationals in China.

You may also be interested in...



J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible

Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson's Relaunch

JP Morgan analysts had questions and J&J CEO Alex Gorsky and CFO Joseph Wolk had answers about liability suits alleging that use of the Johnson's brand talcum powder has caused mesothelioma or ovarian cancer. On the Johnson's brand outlook following its relaunch as a natural product line, Gorsky says sales were a key driver in the firm's consumer health sales in the 2018 third quarter. China, meanwhile, is a model for growing sales online, he says.

J&J Creates ONE China OTC As Country’s Largest Consumer Health Firm

Merging Shanghai Johnson & Johnson and Xian Janssen business divisions makes ONE China OTC the largest consumer health care product company in China. The move “is part of a broader Johnson & Johnson strategic initiative to leverage the company’s breadth and scale in China,” says Mike Hsu, ONE China OTC general manager.

Topics

Related Companies

UsernamePublicRestriction

Register

RS151956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel